# Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions

> **NCT01074450** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pramipexole Dihydrochloride
- **DRUG:** Pramipexole Dihydrochloride

## Key facts

- **NCT ID:** NCT01074450
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074450, "Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01074450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*